Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2025 07:00 ET | Source: Purespring Therapeutics

Purespring to present three posters at the American Society of Nephrology Kidney Week 2025

New information to be presented on the study design and methodology of Purespring’s Phase I/II trial of PS-002, an AAV-based therapy delivering the complement factor I to podocytes in patients with...
October 14, 2025 07:00 ET | Source: Purespring Therapeutics

Purespring Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference

Purespring Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference London – 14 October 2025 - Purespring Therapeutics, a precision nephrology company focused on transforming...
September 10, 2025 07:00 ET | Source: Purespring Therapeutics

Purespring Therapeutics to Participate in the 2025 BofA Healthcare Trailblazers Private Company Conference

London – 10 September 2025 - Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announced that members of its management team will...
August 05, 2025 07:00 ET | Source: Purespring Therapeutics

Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)

First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025UK Clinical Trial Application (CTA) approval shortly follows U.S. IND clearance and granting of European Medicine Agency...
August 05, 2025 02:00 ET | Source: Purespring Therapeutics

Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)

First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025UK Clinical Trial Application (CTA) approval shortly follows U.S. IND clearance and granting of European Medicine Agency...
July 09, 2025 07:00 ET | Source: Purespring Therapeutics

Purespring Therapeutics announce FDA IND clearance for Phase I/II clinical trial for primary IgA nephropathy (IgAN)

PS-002, Purespring’s lead precision nephrology programme, targets the complement pathway known to be a driver of IgA nephropathyIND clearance follows the granting of European Medicine Agency (EMA)...
July 09, 2025 02:00 ET | Source: Purespring Therapeutics

Purespring Therapeutics announce FDA IND clearance for Phase I/II clinical trial for primary IgA nephropathy (IgAN)

PS-002, Purespring’s lead precision nephrology programme, targets the complement pathway known to be a driver of IgA nephropathyIND clearance follows the granting of European Medicine Agency (EMA)...
April 28, 2025 07:00 ET | Source: Purespring Therapeutics

Purespring Therapeutics granted European Medicines Agency (EMA) orphan drug designation for PS-002 for the treatment of patients with primary IgA nephropathy (IgAN)

EMA designation provides orphan status to medicines being developed for rare conditions that are intended for the diagnosis, prevention or treatment of diseases affecting fewer than 5 in 10,000 people...
April 28, 2025 02:00 ET | Source: Purespring Therapeutics

Purespring Therapeutics granted European Medicines Agency (EMA) orphan drug designation for PS-002 for the treatment of patients with primary IgA nephropathy (IgAN)

EMA designation provides orphan status to medicines being developed for rare conditions that are intended for the diagnosis, prevention or treatment of diseases affecting fewer than 5 in 10,000 people...
March 12, 2025 03:00 ET | Source: Purespring Therapeutics

Purespring Therapeutics appoints Haseeb Ahmad as Chief Executive Officer

Haseeb Ahmad brings over 25 years of leadership experience in life sciences, most recently serving as President of Novartis Europe and will lead the Company as it advances pioneering kidney disease...